pbserum enzymes continue to expand in the Middle East
This new launch follows a trend of expansion of the Spanish brand after its success in Europe and the Americas, with a significant presence in countries such as Mexico, Colombia and Argentina. Today, pbserum is already present in more than 50 countries around the world
The Spanish brand launched by the Proteos Biotech laboratory, pbserum, is betting on the Middle East market with the launch of one of its lines in Qatar on September 1.
Thus, the brand will arrive in the country with one of its star lines, the Slim+, Smooth+ and Drain+ products that make up the Plus line, based on the combination of collagenase, hyaluronidase and lipase enzymes, which offer a unique and effective treatment for various pathologies such as cellulite, fibrosis or localized fat.
Until now, the brand known for its innovative enzymatic treatments and its applications in aesthetic medicine was already present in countries in the area such as Jordan, United Arab Emirates, Kuwait, Lebanon and now in Qatar through Vitateck, the company that will manage its distribution in the country.
This new launch follows a trend of expansion of the Spanish brand after its success in Europe and the Americas, with a significant presence in countries such as Mexico, Colombia and Argentina. Today, pbserum is already present in more than 50 countries around the world.
The success of its treatments lies in the commitment of Proteos Biotech, the laboratory in charge of its production, to biotechnology and research applied to aesthetic medicine. The company offers facial treatments focused on reducing expression lines, blemishes or acne marks, among others, as well as body treatments for fibrosis, scars or cellulite.
Manufactured in Albacete and Barcelona, pbserum enzymes have high quality standards and scientific backing for their manufacture and clinical and commercial supply. It is the first therapeutic system based on recombinant enzymes.
With this new launch, the company continues to reap the rewards of its commitment to innovation and development in the sector and continues to consolidate its position as a world leader in aesthetic medicine and dermatological treatments.